The Food and Drug Administration (FDA) in the United States has approved the cabozantinib (Cabometyx) plus nivolumab (Opdivo) combination for first-line treatment of advanced renal cell carcinoma (RCC) based on the results of the Checkmate 9ER trial. Around 20-30% of people are diagnosed with advanced RCC, and 30% of people treated for early stage RCC go on […]
The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]
In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]
In this study, two doses of cabozantinib were tested in combination with atezolizumab for untreated advanced renal cell carcinoma (RCC). Cabozantinib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), while atezolizumab is an immune checkpoint inhibitor. Two doses of cabozantinib were tested; 40 mg and 60 mg. The data were fairly comparable […]
The COSMIC-021 clinical trial investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC). In this video interview, Dr Monty Pal from the City of Hope Hospital in California discusses the side effects from this combination of drugs. There were two groups of patients; one on 60 mg of cabozantinib plus […]
In this video interview with Dr Monty Pal from the City of Hope Hospital in California, treatment of non-clear cell renal cell carcinoma (RCC) with a combination of cabozantinib plus atezolizumab is discussed. Most research is focussed on clear cell RCC; however, non-clear cell RCC accounts for about 25% of all RCC diagnoses and usually […]
Sarcopenia is the loss of muscle mass along with reduced muscle strength and/or impaired physical performance. It usually occurs in older people. In this study, the researchers looked at the presence of sarcopenia and its impact on survival in patients with metastatic renal cell carcinoma (RCC) treated with cabozantinib. Twenty eight (28) patients were evaluable […]
This recent retrospective study included 84 patients with metastatic renal cell carcinoma (RCC) who were treated with cabozantinib after being treated with nivolumab. Most of the patients had poor- or intermediate-risk RCC and all patients received a tyrosine kinase inhibitor (TKI) as first-line therapy, followed by nivolumab in the second- or third-line. Median progression-free survival […]
A retrospective study published in the European Journal of Cancer this month looked at the activity of cabozantinib after immune checkpoint inhibitors in people with metastatic clear cell renal cell carcinoma (RCC). The overall response rate was 36%, with a median overall survival of 13 months. Cabozantinib appeared to be well tolerated and there were […]
Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
